News and Announcements
OncoPac Global Clinical Study Receives Ethics Approval from Monash Health
- Published February 02, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX: OSL) is a medical device company that focuses on localised treatments for patients with pancreatic and liver cancer. The Company are pleased to announce that they have been granted the Ethical Approval from the Monash Health for its OncoPac global clinical study program that is specialised for pancreatic cancer.
This study will provide a significant clinical study process to date. The Ethics Approval at Monash Health will also facilitate ethics approval for other participating study centres Australia-wide (excluding Western Australia); this in turn will help accelerate the patient recruitment process.
The success of this grant taking place at Monash Health comes after the Company filed its Ethics Committee (HREC) submission during November last year. Monash Health is the largest public health service in Melbourne, that has agreed to lead this Australian study. Monash provides health care services to over 1.5million people per year. This particular health care facility has also be named one of Victoria’s premier cancer facilities.
To date, OncoSil Medical has confirmed the participation of 12 centres for its global pancreatic clinical study program, along with currently being involved in further discussion with seven centres in the UK, Europe and Australia. The Company, will soon start adding new centres to its trail program in the coming months, along with commencing patient recruitment globally.
OnocSil Medical will update the market on the progress of the OncoPaC clinical study program in due course.
OncoSil Chief Executive Officer, Daniel Kenny commented:
“We are extremely pleased to have secured Ethics Approval for our global OncoPaC clinical study program in pancreatic cancer at Monash Health. Monash is a highly regarded cancer centre and is also the lead Australian centre for our clinical study program. With Ethics Approval granted at Monash, it now paves the way for the provision of ethics approvals across other Australian study centres, a pivotal requirement in the study program.”
To view the full announcement, please click here.
Company Updates
The asset class where the market has no vote
Litigation funding returns are decided in a courtroom, not a cycle. Knightsbridge’s Head of Capital is careful to call that a different risk rather than a lower one, and his answer to it is spread, not concentration. Most alternative assets still answer to something. Property answers to rates. Private credit answers to defaults. Even the […]
The listing fee vendors pay whether the house sells or not
Australia’s property portals collect more than $2 billion a year while national listings sit flat. An Australian-built AI platform is targeting the economics, not just the interface. An Australian vendor listing a home pays a vendor-paid advertising fee on top of agency commission. Rama Dwarapudi, Founder and Chief Executive Officer of RealSearch, puts a typical […]
Reinventing the Condom: How an Australian Deep-Tech Startup Plans to Disrupt a $12 Billion Market
For more than half a century, the global condom industry has remained fundamentally unchanged, constrained by standard materials like latex and solid synthetic polymers. Despite widespread consumer demand for better alternatives, product design has treated the device strictly as a mechanical barrier, sacrificing feel for function. Sydney-based Eudaemon Technologies is setting out to upend that […]
Backed By Leading Investment Groups and Family Offices
